Identification of the Hub genes and inhibitors associated with hypertension in children with obesity using WGCNA

TL;DR

This study identifies S100A9 as a key gene in obesity-related hypertension in children and suggests a potential inhibitor for treatment.

Contribution

The study introduces S100A9 as a novel therapeutic target for childhood obesity-related hypertension.

Findings

S100A9 increases ROS and reduces NO, impairing endothelial function in obese children.

ABR-215757 (Paquinimod) shows therapeutic potential by improving endothelial function and reducing inflammation.

Five differentially expressed genes, including S100A9, were identified in children with obesity.

Abstract

Childhood obesity is an escalating public health issue linked to comorbidities such as hypertension, which poses significant cardiovascular risks. This research aims to elucidate the molecular pathways connecting obesity to hypertension in pediatric populations, with a focus on the gene S100A9 (S100 Calcium Binding Protein A9), implicated in inflammatory responses and vascular dysfunction.

We analyzed gene expression data from GSE87493 dataset and performed Weighted Gene Co-expression Network Analysis (WGCNA) to identify the differentially expressed genes (DEGs) and co-expression modules associated with childhood obesity. Functional assays were conducted to investigate the role of S100A9 in vascular endothelial dysfunction. Besides, small molecule inhibitors targeting S100A9 were screened for therapeutic potential.

Five DEGs, including S100A9, showed distinct expression patterns in children with obesity. Mechanistically, S100A9 increases reactive oxygen species (ROS) levels and reducing Nitric oxide (NO), thereby impairing endothelial function. Small molecule inhibitor ABR-215757 (Paquinimod) was identified as a promising candidate, enhancing tube formation in the human umbilical vein endothelial cells (HUVECs) and reducing inflammatory markers.

Targeting S100A9 may restore endothelial function and offer novel therapeutic strategies for obesity-related hypertension in children. More future research should validate these findings through in vivo models and clinical trials to evaluate the efficacy and safety of S100A9 inhibitors in pediatric populations.

Figures